Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe treatment-resistant depression in Scotland but intravenous ketamine has not, though it ...

RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients ...

Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of esketamine nasal spray as a monotherapy for adults with treatment-resistant depression.If ...

BSA Behavioral Health announced it is expanding its mental health services to include Spravato (esketamine) nasal spray, for ...

What is Spravato? Medicare may cover Spravato, a drug that contains a derivative of ketamine called esketamine, for specific mental health conditions.

Magnesium may help ease depression by supporting brain function and mood regulation, especially in people with low magnesium levels.

Spravato is the brand name for an esketamine nasal spray that the FDA has approved for treatment-resistant depression. A doctor may prescribe the drug for depression that has not responded to ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become the first FDA-approved psychedelic?

Ketamine seems to be everywhere — from the nightclub to the psychiatric clinic. Among its growing number of users is Elon Musk, who says he takes ketamine every two weeks for depression as prescribed ...